EU Clinical Trial 2018-002062-39

A randomized, double-blind, multicenter study assessing short (16 weeks) and long-term efficacy (up to 1 year), safety, and tolerability of 2 subcutaneous secukinumab dose regimens in adult patients with moderate to severe hidradenitis suppurativa  May 6, 2019

Main objective of the trial: To demonstrate the efficacy of secukinumab compared to placebo with respect to HiSCR after 16 weeks of treatment.

Parties

Sponsors
Countries
AR BE BG BR CA CH CO CZ DE DK ES FR GB GR GT HR HU IL IN IT LB LT MY NL PH PL RU SG SK TR US VN ZA
Keywords
AIN457 Hidradenitis suppurativa Secukinumab

JSON preview

Similar records

Title